Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Irina Golovleva

Irina Golovleva

Umeå University, Sweden

Title: Genetic studies of hereditary retinal degenerations in northern Sweden

Biography

Biography: Irina Golovleva

Abstract

Blindness is a severe visual impairment with diminished or total vision loss. An average estimate of blind people in industrialized countries is 1-2/2000 compared to 5-10/1000 in developing countries. Disturbed anatomical structures and functions of cornea and retina are known to cause impaired vision. Retinitis pigmentosa, hereditary maculopathies and age related macular degeneration are part of a very heterogeneous group, called retinal dystrophies and degenerations associated with mutations in more than 250 loci and genes. In northern Sweden the presence of all hereditary disorders is relatively high due to a disposition of genetic abnormality in a geographically isolated area back in time. The frequency of retinitis pigmentosa (RP) is 1/3500 worldwide, however, in northern Sweden it is 1/2000 due to limited migration and a 'founder' effect. RP shows autosomal dominant (10%), autosomal recessive (50-60%) and X-linked inheritance (15%). In our research using linkage analysis, copy number variants (CNV) analysis and next generation sequencing we uncovered genetic defects in autosomal recessive RP of Bothnia type (RLBP1), autosomal dominant RP with incomplete penetrance (RP11) (PRPF31), cone dystrophy (CORD5), Stargardt disease and Leber Congenital Amaurosis (ABCA4, CRB1) and other severe RP forms (MERTK, EYS). Pathogenic mutations were detected in 53% of patients. Our data provide valuable information on the molecular mechanisms of RP evolvement and are useful in development of therapeutic strategies. Genetic diagnosis allows molecular genetic testing and genetic counselling of the patients and their families and also their inclusion to clinical trials of new treatments.